Serotonin, Anxiety and Visceral Sensation

U

University of Sussex

Status

Completed

Conditions

Healthy

Treatments

Drug: Citalopram 20mg
Drug: Placebo

Study type

Interventional

Funder types

Other

Identifiers

NCT06212284
ER/JL332/9

Details and patient eligibility

About

The goal of this crossover study was to learn about the potential regulatory role of serotonin in interoceptive processing and its relationship to levels of state anxiety. This experiment directly compared the impact of a selective serotonin reuptake inhibitor (SSRI) (20mg CITALOPRAM) to that of a PLACEBO on the neural processing of ordinary interoceptive sensations and the relationship of these influences to anxious states. Healthy young volunteers completed the visceral interoceptive attention task with each treatment condition (citalopram and placebo). The task involves focusing attention on heart, stomach, or visual sensation control while scanned with functional magnetic resonance imaging (fMRI). The difference in haemodynamic response between interoceptive sensation(s) and visual sensation (i.e. the relative interoceptive response) is compared between treatment conditions. State anxiety is measured at each test period. It is used to test for a moderating effect of state anxiety on the influence of serotonin in interoceptive processing and used post-hoc to explore associations between changes in state anxiety and changes of interoceptive relative interoceptive response due to the SSRI.

Enrollment

31 patients

Sex

All

Ages

18 to 35 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

  • healthy volunteer

Exclusion criteria included:

  • the presence of significant ongoing medical condition;
  • pregnancy or breastfeeding;
  • currently taking any medication (excluding contraceptive pill);
  • first-degree family history of bipolar disorder;
  • an indication of current or historical mental health disorder,
  • MRI scanner contraindications (e.g. metallic implants)
  • data that is unanalyzable due to movement
  • excessive side effects of the drug (e.g. nausea)

Trial design

Primary purpose

Other

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Quadruple Blind

31 participants in 2 patient groups

citalopram first, placebo second
Other group
Description:
Citalopram was taken first. Placebo was taken at least 7 days later.
Treatment:
Drug: Placebo
Drug: Citalopram 20mg
placebo first, citalopram second
Other group
Description:
Placebo was taken first. Citalopram was taken at least 7 days later.
Treatment:
Drug: Placebo
Drug: Citalopram 20mg

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems